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Locus
aGvHD
Risk #A #P HR Range p Value Range DSS Range
DSS
Mean
A* Low 11 389 0.64-1.57 0.2-0.8 1.04-5.66 2.62
High 4 214 1.78-3.45 \0.001-0.003 1.04-4.3 2.39
B* Low 4 200 1.28-1.48 0.118-0.538 1.74-2.81 2.53
High 2 30 3-3.34 \0.001-0.015 1.06-1.06 1.06
Cw* Low 18 578 0.46-2.88 0.057-0.899 1.52-23.9 15.1
High 17 600 1.67-6.22 0.001-0.043 1.52-23.86 15.97
DRB1* Low 25 729 0.47-2.25 0.079-0.985 1.3-13.33 4.91
High 2 76 2.13-3.19 \0.001-0.003 4.02-10.41 7.22
DQB1* Low 24 900 0.57-1.58 0.062-0.98 0.24-20.61 10.37
High 3 114 1.75-2.81 0.002-0.017 1.38-20.61 13.74
Oral Presentations S173combinations are 13.88 and 15.33, respectively. The following table
summarizes DSS means and ranges for high and low risk combina-
tions.
(Table 1) #A: # of allele combinations analyzed by Histocheck
#P: # of donor/patient pairs that have all the analyzed combina-
tions
HR: Hazard Ratios of developing severe aGvHD
P values: for the corresponding estimated hazard risk
Conclusion: Our analysis demonstrates that means and ranges of
DSS were interchangeable among high and low risk allele combina-
tions within loci A, B, and Cw. In loci DRB1 and DQB1 DSS means
were higher in the high risk combinations but the ranges remain
overlapping. This analysis does not support selecting donors for
HSCT recipients on the basis of low HistoCheck scores.IMMUNE RECONSTITUTION50
CYTOTOXIC T LYMPHOCYTES (CTL) SPECIFIC FOR CMV, ADENOVIRUS,
AND EBV CAN BE GENERATED FROM NAIVE T CELLS FOR ADOPTIVE IM-
MUNOTHERAPY
Hanley, P.1, Savoldo, B.1, Cruz, C.R.1, Leen, A.M.1, Rodgers, J.2,
Liu, H.1, Gee, A.P.1, Heslop, H.E.1, Rooney, C.M.1, Brenner, M.K.1,
Shpall, E.J.3, Bollard, C.M.1 1Baylor College of Medicine, Houston, TX;
2Baylor College of Medicine, Houston, TX; 3M.D. Anderson Cancer Cen-
ter, Houston, TX
Adoptive immunotherapy with peripheral blood (PB)-derived
CMV/Ad/EBV-specific CTL generated from seropositive donors ef-
fectively prevents viral disease after Peripheral Blood StemCell Trans-
plant (PBSCT),but this optionhasnotbeen feasiblewhen thedonorT-
cells are naive. PBSCT fromCMV-seronegative (CMVneg) donors to
CMV-seropositive (CMVpos) recipients produces a high incidence of
CMV infection since donor T-cells are naı¨ve to this virus. Umbilical
cord blood (CB) is an important source of stem cells for allotransplant
patients lacking human leukocyte antigen (HLA)-matched donors. T-
cells inCBgrafts are, however, also virus-naı¨ve, leading tohigher infec-
tions rates with CMV, EBV, adenovirus (Ad) and other viruses. Irre-
spective of whether the naive T-cells are sourced from CB or
CMVneg PB, CTL generation for clinical use from these donors has
been unsuccessful. We have now overcome this problem and can rou-
tinely generate CMV, Ad and EBV specific CTL fromCB and CMV-
specific CTLs from seronegative PB for clinical use. We used an
Ad5f35CMVpp65 vector to transduceCBor PBderived dendritic cells
and stimulated virus-specific CTL in the presence of IL-7, IL-12 and
IL-15.Thiswas followed by 2 stimulationswith autologous EBV-lym-
phoblastoid cell lines (LCL) transduced with the same vector. CB-de-
rived CTL were predominantly CD8+ (mean 87%;range 81-94) and
had significant cytotoxicity against CMVpp65, Adhexon/penton and
LCL targets. In addition, we generated CMVpp65, Adhexon/penton
and LCL-specific responses from the PB of 4 CMVneg adult donors,
which produced a mean of 92 (range 50-126), 163 (range 69-293),
and 62 (range 37-86) SFC to CMVpp65 respectively. Neither CB
nor CMVneg-derived CTL responded to irrelevant peptides. Of
note, thevirus-specificT-cells expanded fromCBandCMVnegdonorsderivedonly fromT-cellswithanaivephenotype (CD45RA+/CCR7+).
Moreover, both CB and CMVneg-derived CTL recognized ‘‘uncon-
ventional’’ CMVpp65 epitopes, as identified by overlapping pp65 pep-
tide pools and confirmed by IFN-g ELISPOT as well as multimer
analysis. In HLA-A2+ subjects, naive-derived CTL did not recognize
conventional HLA-A2 associated CMV pp65 epitopes such as NLV,
suggesting an inherent differencebetweennaı¨ve andmemoryT-cell re-
sponses to CMV. In summary, virus-specific responses T-cell re-
sponses can be obtained even from CB and virus-naive adult donors
andmayallowpreventionand treatmentof viraldisease in the recipients
of these allografts.
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DENDRITIC CELL FACILITATE THYMIC RECOVERY AND ENHANCE IM-
MUNE RECONSTITUTION AFTER HEMATOPOIETIC STEM CELL TRANS-
PLANT
Langfitt, D., Wallace, N., Dallas, M.H. St Jude Children’s Research
Hospital, Memphis, TN
After hematopoietic stem cell transplantation (HSCT), the first
committed cells to engraft in the thymus are dendritic cells (DCs).
The role of thymic DCs in T cell production by ensuring efficient
tolerance and selection has been well demonstrated, however the
role of thymic DCs in facilitating donor engraftment has not been
investigated. Here we show addition of ex-vivo generated DCs
accelerates thymic engraftment as well as enhance T cell recovery
after HSCT. Control group received 103 lin-sca-1+c-kit+ (LSK)
(CD45.2) hematopoietic stem cell progenitors while the DCs group
received 103 LSK (CD45.2) cells along with 103 ex-vivo generated
DCs. DCs were generated using bone marrow from GFP+ CD57/
Bl mice (CD45.1/GFP+) and cultured for 7 days with GMCSF. On
the day of HSCT, C57/BL (CD45.1) recipients received lethal radi-
ation at 1000 cGy. At 4 and 7 days after HSCT, thymuses of theDCs
group had GFP+ CD11c+ cells present in the medullary region con-
firmed by immunohistochemistry and contained 1.8 and 4.2- fold,
respectively, higher number of thymocytes compared to control
group (p\0.05). Furthermore, thymuses of the DCs group showed
a 3.2 and 7.4-fold, respectively, higher number of thymoctyes
derived from donor LSK (CD45.2) cells compared to the control
group (p\0.05 and p\0.007). Two and four weeks after HSCT,
peripheral blood of DCs group contained at least 2.6 and 4.8-fold,
respectively, higher numbers of CD3+ cells derived from donor
LSK (CD45.2) cells compared to the control group (p\0.05).
Here, we demonstrate that ex-vivo generatedDCs efficientlymigrate
and home to the thymic medulla and hasten thymic recovery as dem-
onstrated by the higher number of total thymoctyes. Furthermore,
DCs facilitate thymic engraftment as shown by increase number of
donor thymoctyes. Lastly, recipients of DCs have earlier generation
of de-novo donor derived CD3+ T cells in the peripheral blood. By
using the GFP+ (CD45.1) cells along with donor LSK (CD45.2),
we were able to confirm that the facilitation of early thymic recovery
was due to the increased engraftment of the donor cells rather than
autologous recovery of the host. Thus, this study suggests that
DCs committed prior to thymic entry maintains the ability to
home to the medullary region and facilitate thymoctye recover and
hasten immune reconstitution after HSCT.52
CD40-ACTIVATED B CELLS MIGRATE TOWARDS SECONDARY LYMPHOID
ORGANS AND INTERACT DYNAMICALLY WITH T CELLS
Klein-Gonzalez, N.1, Balkow, S.2, Kondo, E.1, Grabbe, S.2, Liebig, T.1,
Shimabukuro-Vornhagen, A.1, Bloch, W.3, von Bergwelt-Baildon, M.1
1University Hospital of Cologne, Germany; 2 Johannes GutenbergUniver-
sity, Mainz, Germany; 3Deutsche Sporthochschule Ko¨ln, Germany
B cells have been demonstrated to present antigen to T cells in
vivo. CD40-activation dramatically improves antigen presentation
by normal and malignant B cells and has therefore been studied as
an approach to generate autologous ‘‘non-artificial’’ antigen present-
ing cells for active immunotherapy. Furthermore, CD40-B cells have
recently been shown to expand tumorantigen and viral specific CTL
S174 Oral Presentationsas well as regulatory T cells and are therefore of great interest for
post-transplant immunotherapy. Human B cells when activated via
CD40-L/IL-4 can be expanded from small amounts of peripheral
blood in 12-14 days. CD40-activated B cells can prime naı¨ve T cells,
expand memory T cells and express important surface homing mol-
ecules. Nevertheless, it remains unclear whether such cells have the
property to attract and interact withT cells in a physiological context
and whether CD40-activated B cells migrate to secondary lymphoid
organs (SLO) in vivo, a necessary step for an antigen-presenting cell
(APC) to induce immunity. To address this question we established
a platform to generate murine CD40-activated B cells. At day 14 of
culture, these cells are .95% CD19+ and CD80/86/MHCI/
MHCIIhi.Murine CD40-activated B cells present a ‘homing pheno-
type’; migrate towards SLO chemokines such as CCL19, CCL21
and CXCL13; and induce T-cell chemotaxis in vitro. Upon
CD40L activation, B cells up-regulate CCR7 while down-regulate
CXCR5 expression which suggests direction of activated B cells
towards the B-zone-T-zone boundary. We compared the homing
of GFP+ CD40-activated B cells to resting GFP+ B cells and
show for the first time that CD40-activated B cells home to SLO
significantly more efficiently than resting B cells. Furthermore,
CD40-activated B cells localize in B-cell areas, and a significant frac-
tion move to the B-T boundary close to the T-cell zone. To dissect
T-cell-APC interactions on a single cell we analyzed three-dimen-
sional migration in collagen matrix. Interestingly, antigen-loaded
CD40-activated B cells differ from immature andmature DC by dis-
playing a rapid migratory pattern undergoing highly dynamic, short-
lived (7.5 min) and sequential interactions with cognate T cells.
Taken together, these data reveal that CD40-activated B cells can
home to secondary lymphoid organs and interact dynamically with
T cells thus underlining their potential as cellular adjuvant for cancer
immunotherapy.53
MULTIVIRUS-SPECIFIC T CELL IMMUNOTHERAPY TO PREVENT OR
TREAT INFECTIONS OF ALLOGENEIC STEM CELL TRANSPLANT RECIPI-
ENTS
Leen, A.M., Gerdemann, U., Christin, A., Ramos, C.A., Heslop, H.E.,
Brenner, M.K., Rooney, C.M., Vera, J.F. Baylor College of Medicine,
The Methodist Hospital, Texas Children’s Hospital, Houston, TX
Viral infections causemorbidity andmortality in allogeneicHSCT
recipients. We and others have successfully generated and infused
adoptive T-cell lines specific for EBV, CMV and Adenovirus using
monocytes and EBV-transformed lymphoblastoid cell (EBV-LCL)
gene-modified with an adenovector as antigen presenting cells
(APCs). We have shown that as few as 2105/kg trivirus-specific
cytotoxic T lymphocytes (CTL) proliferated by several logs post-
infusion and appeared to prevent and treat even severe viral disease
resistant to other available therapies.Despite the encouraging clinical
results, broader implementation of this ‘‘trispecific’’ CTLapproach is
limited by high production costs, complexity of manufacture and the
prolonged time (4-6 weeks for EBV-LCL generation, and 6-8 weeks
for CTL manufacture – total 10-14 weeks) for preparation.
To overcome these manufacturing limitations we have developed
new, GMP-compliant strategies. In place of adenovectors we now
use DCs nucleofected with non-viral DNA plasmids encoding
LMP2 and BZLF1 (EBV), Hexon and Penton (Adv), pp65 (CMV)
and Large T antigen (BK virus) to stimulate T-cells. Furthermore,
by pooling nucleofected DCs prior to PBMC stimulation, we can
reproducibly generate multivirus-specific CTL lines reactive against
all the stimulating antigens, without discernible antigenic competi-
tion. Secondly, we have demonstrated that the culture of activated
T-cells in the presence of IL-4 (1,000U/ml) and IL-7 (10ng/ml) pro-
motes the survival of both high and low frequency antigen-specific
CTL and sustains the breadth of reactivity in our lines. Finally, we
have replaced traditional plastic cultureware with a new, gas perme-
able culture device (G-Rex) which promotes the expansion and
survival of large cell numbers in a closed systemwithminimal techni-
cian intervention. By implementing these changes we can now pro-
duce multispecific CTL targeting EBV, CMV, Ad, and BK virus at
a cost per 106 cells that is reduced by.90%, and in just 10 days rather
than 10 weeks using an approach that may be extended to additional
protective viral antigens. Our approach should be of value for pro-phylactic and treatment applications for high risk allogeneic HSCT
recipients.54
FAST B- AND NK-, RECONSTITUTION EARLY AFTER UNRELATED CORD
BLOOD TRANSPLANTATION COMPARED TO (UN)RELATED BONE MAR-
ROW TRANSPLANTATION IN CHILDREN
de Pagter, P.J.A.1, Lindemans, C.1, Keukens, L.1, Belitser, S.V.2, de
Weger, R.A.3, van der Weide, P.3, Baeten, E.4, de Gouw, A.P.4,
Bierings, M.1, Van Baarle, D.1,4, Bloem, A.4, Boelens, J.J.1 1University
Medical Center Utrecht, Netherlands; 2Utrecht Institute for Pharmaceu-
tical Sciences (UIPS), University of Utrecht, Netherlands; 3University
Medical Center Utrecht, Netherlands; 4University Medical Center
Utrecht, Netherlands
Early immune reconstitution after allogeneic-haematopoietic
stem cell transplantation (HSCT) is important for controlling
infectious complications. We compared T-, B- and NK-cell recon-
stitution during the first 100 days after bone marrow (matched sib-
ling: id-SIB, unrelated bone marrow: u-BM) or cord blood (u-CB)
HSCT in a single-center prospective study among pediatric patients.
Between 2006 and 2008, 103 patients were included with a median
age of 5 years (range 0-21); 33 recipients received id-SIB, 33 u-BM
and 37 u-CB grafts. All patients received myelo-ablative condition-
ing and in the unrelated donor setting thymoglobulin (10 mg/kg)
was added from 4 to 2 days before SCT. The number of CD3+ cells
in the graft graft was for uCB 8*10e6 (range 8*10e5 – 4*10e7)/kg, for
id-SIB 4*10e7 (range 1 – 9*10e7)/kg and for u-BM 5 *10e7 (range
1*10e7 – 5*10e8)/kg.
Statistical analysis was performed by Kruskal-Wallis rank sum
tests and Wilcoxon tests with continuity corrections.
Median follow up was 16months (range 1-28); overall survival was
73%. Probability of neutrophil at day 60 did not differ among id-SIB
u-BM and u-CB recipients (median 23 days, range 3-60 after HSCT,
p5 0.092). Overall T-cell (CD3+) reconstitution (first 100 days) was
similar between the 3 groups, but CD8 +T-cell numbers were
higher after id-SIB- and u-BM compared to u-CB HSCT (155 and
309 versus 52 CD8 +T-cells/uL, p5 0.002). Interestingly, NK-
cell and B-cell numbers were significantly higher in u-CB compared
to id-SIB (p5 0.018 and p5 0.0003, resp.) and u-BM recipients
(p5 0.036 and p5 0.0003, resp.) within the first 100 days. On the
long term, in u-CB and id-SIB recipients higher ratios of nave
CD4+ and CD8 T-cells were found (u-CB: 62% and 87%, id-SIB:
55% and 57%) compared to u-BM recipients (30% and 17%) at
1 year after HSCT (p5 0.050 and p5 0.029).
Higher NK- and B-cell numbers early after HSCT indicate
a better proliferative capacity of these u-CB stem cells compared
to id-SIB and u-BM stem cells. We speculate the observed delayed
T-cell reconstitution after u-CB HSCT is caused by a deeper in
vivo depletion using the same dose of thymoglobuline in a setting
of u-CB grafting where the T-cell dose is 1 log lower than an u-BM
graft. Insight in the early immune reconstitution is essential for
the future development of immune-mediated therapies and the
development of optimal graft specific conditioning regimens to
prevent prolonged post-HSCT lymphopenia and the associated
viral complications.55
NOVEL H1N1 INFLUENZA A (S-OIV) INFECTION IN RECIPIENTS OF HE-
MATOPOIETIC STEM CELL TRANSPLANTATION
Strasfeld, L.1, Espinoza, L.1, Green, J.2, Graeme, F.1, Meyers, G.1,
Ball, E.2, Castro, J.2, Mulroney, C.2, Curtin, P.2, Maziarz, R.1,
Taplitz, R.2 1Oregon Health and Sciences University, Portland, OR;
2University of California, San Diego, La Jolla, CA
Background: Respiratory virus infections cause significant morbid-
ity in stem cell transplant patients. Novel H1N1 Influenza A (Swine
Origin Influenza A, S-OIV) can result in severe disease in immuno-
compromised hosts.
Methods: Eleven hematopoietic stem cell transplant (HSCT) pa-
tients with influenza A were identified between 4/09 and 7/09.
This retrospective analysis summarizes the patient demographics,
clinical presentation, influenza testing, treatment, and outcome in
these S-OIV-infected HSCT recipients.
